— Know what they know.
Not Investment Advice

STIM NASDAQ

Neuronetics, Inc.
1W: +17.3% 1M: -18.2% 3M: +19.8% YTD: +55.6% 1Y: -24.3% 3Y: +103.6% 5Y: -55.6%
$2.19
-0.05 (-2.23%)
 
Weekly Expected Move ±7.9%
$2 $2 $2 $2 $2
NASDAQ · Healthcare · Medical - Devices · Tech Score Neutral · Power 43 · $170.7M mcap · 29M float · 6.15% daily turnover · Short 60% of daily vol
Credit Risk of going bust: higher than 90% of companies Debt: 33.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 93%), Neuronetics, Inc. would be worth roughly what it owes.
Total debt $86.5M against a stock market value of $170.7M.
Distance to default 1.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.8M (short-term plus half of long-term), stock volatility 110.4%; Altman Z -3.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider+$0.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$170.7M
52W Range0.8-3.44
Volume1,098,547
Avg Volume1,776,464
Beta1.20
Dividend—
Analyst Ratings
6 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEODaniel L. Reuvers
Employees658
SectorHealthcare
IndustryMedical - Devices
IPO Date2018-06-28
3222 Phoenixville Pike
Malvern, PA 19355
US
610 640 4202
About Neuronetics, Inc.

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Chernett Jorey P-Purchase 14,000 $3.16 2026-08-14
Chernett Jorey S-Sale 100 $5.00 2026-08-13
Naor Nir A-Award 500,000 — 2026-07-23
Naor Nir 0 — 2026-07-23
Chernett Jorey P-Purchase 35,000 $1.78 2026-07-14

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms